Scholarlink

<p>Diabetes mellitus is a complex, chronic metabolic disease with a multifactorial pathogenesis involving genetic predisposition and environmental factors. Recently, epigenetics, particularly RNA methylation modifications, have gained increasing attention. N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) is one of the most prevalent RNA modifications, and methyltransferase-like 3 (METTL3), the core component of the m<sup>6</sup>A methyltransferase complex, plays a pivotal role in regulating key physiological and pathological processes, including islet β-cell function, insulin regulation, and glucose metabolism. This article reviews the mechanisms by which METTL3 and m<sup>6</sup>A modifications contribute to the development of diabetes and its complications. Preclinical studies suggest METTL3 a promising target, but future research should focus on identifying safe, effective regulatory strategies for its clinical application. Overall, METTL3 and its m<sup>6</sup>A-mediated modifications present promising novel therapeutic targets for the prevention and treatment of diabetes mellitus, providing novel theoretical insights and strategies for managing the disease and its complications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

METTL3-mediated m6A methylation: implications for diabetes pathogenesis and therapeutic potential

  • 期刊论文

  • 发表日期：

    2025年9月18日

查看全文
  • Yingjie Wang,
  • Kexin Zhang,
  • Xiaofei Zhang,
  • Chengxia Kan,
  • Sufang Sheng,
  • Xiaodong Sun

摘要

Diabetes mellitus is a complex, chronic metabolic disease with a multifactorial pathogenesis involving genetic predisposition and environmental factors. Recently, epigenetics, particularly RNA methylation modifications, have gained increasing attention. N6-methyladenosine (m6A) is one of the most prevalent RNA modifications, and methyltransferase-like 3 (METTL3), the core component of the m6A methyltransferase complex, plays a pivotal role in regulating key physiological and pathological processes, including islet β-cell function, insulin regulation, and glucose metabolism. This article reviews the mechanisms by which METTL3 and m6A modifications contribute to the development of diabetes and its complications. Preclinical studies suggest METTL3 a promising target, but future research should focus on identifying safe, effective regulatory strategies for its clinical application. Overall, METTL3 and its m6A-mediated modifications present promising novel therapeutic targets for the prevention and treatment of diabetes mellitus, providing novel theoretical insights and strategies for managing the disease and its complications.